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Background
Primary hyperparathyroidism (pHPT) is the third most common endocrine disease. Incidence is three to four times greater in females and increases with age [1] . The characteristics of pHPT is a high 'normal' calcium concentration caused by an excess secretion of the parathyroid hormone (PTH), most often from a single pathologic parathyroid gland, a parathyroid adenoma [2] . Most patients with pHPT today do not exhibit the classical, overt symptoms of bone and stone disease traditionally associated with pHPT [3, 4] . In the majority of cases, pHPT occurs sporadically. In approximately 10% of the cases, pHPT is a component of a hereditary disorder, mainly inherited as autosomal dominant traits [5] .
The diagnosis often goes undetected for a long period of time. Neuromuscular, psychiatric, cognitive as well as cardiovascular symptoms and signs are often exhibited and may be attributed to the disease but are, however, not disease-specific. Hitherto, the causal links between pHPT and these nonclassical symptoms and signs are not altogether clear. The PTH is the most important circulating regulator of calcium homoeostasis, and the extracellular, free calcium ion (Ca 2+ ) is involved in most physiological processes in the human body. Precise control of ionized calcium concentration (iCa 2+ ) is necessary in order to ensure optimum control, and calcium-sensing receptors are widely distributed throughout the system [6, 7] . The PTH secretion is inversely related to the iCa 2+ level, and the relation is characterized by a steep sigmoidal curve [8] . Review treatment of pHPT. The surgical procedure, often equivalent to removal of a single parathyroid adenoma, is safe and effective and associated with minimal morbidity even in older patients [9, 10] . For patients with classic symptoms of pHPT, the indication for parathyroidectomy (PTX) is undisputed [11, 12] . The alternative to surgical treatment is active surveillance occasionally combined with medical treatment, for example with bisphosphonates, in order to manage any complications. Controversy remains, however, as to what is the best treatment for patients with those nonclassical symptoms and here is where referral patterns differ [11, 13, 14] . Many patients who would potentially gain from PTX today end up in a grey zone regarding treatment and follow-up, and an untreated disease may progress silently until complications occur. The main focus of this review was to bring attention to the current opinions of what is the best treatment for patients with pHPT.
Evolving concepts of primary hyperthyroidism
The history of parathyroid surgery is relatively short. It took nearly half a century between the first systematical description of 'The morphology of the Glandula Parathyroidea' by Ivan Sandstrom in 1880 and the first therapeutic removal of a pathologic, parathyroid gland [15] . Important insights into the pathophysiology of pHPT were obtained after the first patient was treated by PTX for pHPT in 1925 [16] . The patient, suffering from severe skeletal pain, fatigue and unable to walk, improved miraculously after the removal of a parathyroid adenoma. In that same year, the isolation of PTH opened up new perspectives that increased the understanding of its biological role as well as the pathophysiological effects of excess of the hormone [17] .
Before the 1970s, pHPT was a rarely detected disease associated with notable morbidity, often summarized by the mnemonic 'bones, stones, abdominal groans and psychiatric moans'. The introduction of biochemical screening, allowing for a wide range of indications, aids in revealing hypercalcaemia, and the further development of more exact methods for measuring PTH has contributed to the detection of the full spectrum of the disease. The highest incidence of pHPT, 3-5%, is observed amongst women, and the prevalence increases with age [18] [19] [20] [21] . The female-to-male ratio is 3-4 : 1 except in younger patients where distribution is equal [1, 22] .
Symptomatic pHPT refers to overt symptoms and signs related to the main target organs, the skeletal system and the kidneys (Fig. 1) . The phenotype includes radiological features, defined as osteitis fibrosa cystica which is sometimes associated with fractures, deformities, bone pain, kidney stones, nephrocalcinosis, proximal muscle weakness, peptic ulcer disease, pancreatitis, hypertension and atherosclerotic heart disease as well as neurocognitive symptoms including anxiety and cognitive decline [12] . Asymptomatic pHPT refers to patients with unequivocal biochemical pHPT but without the classical symptoms [4] . It is important to emphasize that the term asymptomatic in this context is not equivalent to 'without symptoms'. Patients often complain of diffuse symptoms such as depression, lack of mental focus, reduced quality of life and muscular weakness. These symptoms are not disease-specific, and the causal link to pHPT is unclear. The main contributing factor to the shift in the clinical presentation of pHPT is probably an iceberg phenomenon with a higher detection rate of patients affected. Studies from China, India and Brazil, amongst other countries, still show a dominant percentage of pHPT patients with classic symptoms and more severe biochemical abnormalities but the differences are being levelled out [23] [24] [25] [26] . Access to biochemical screening of calcium levels seems to be the crucial factor. Development of methods for measurement of intact PTH has contributed to greater specificity and improvement in the discrimination (Table 1) . About 10% of pHPT patients have been found to have a PTH within the upper half of the normal reference range [27, 28] . A new entity with an isolated elevation of PTH, normocalcaemic HP, has emerged and is currently being explored [29] [30] [31] . The definition normocalcaemic is based on normal total and ionized calcium concentrations and requires the measurement of iCa 2+ (Table 1 ) [32] .
Causes of pHPT
Several causative genetic events have been identified, both in sporadic and hereditary forms. Hereditary pHPT accounts for about 10% of all pHPT cases and may emerge isolated or as part of a syndrome. Hereditary pHPT is characterized by earlier onset and a higher rate of multiglandular involvement [33] . Constitutional mutations of the tumour suppressor genes, MEN1 (11q13) and CDC73 (1q31.2; hyperparathyroidism-jaw tumour syndrome, HPT-JT) and of the calcium receptor gene CASR (3q21.1, familial hypocalciuric hypercalcaemia, FHH) are the most common variants, and tests for mutational analyses are routinely available. Numerous somatic mutations and possible epigenetic mechanisms have been identified in parathyroid adenomas [34] [35] [36] [37] . MEN1 mutations are commonly seen in parathyroid adenomas whilst CDC73 mutations occur in 70% of parathyroid carcinomas but only in about 2% of parathyroid adenomas [34, 38, 39] . Parathyroid cancer is rare and constitutes less than 1% of all pHPT cases and about 0.005% of all cancers. It occurs isolated or as a part of a complex, hereditary syndrome [2, 34, 40] . Approximately 15% of the HPT-JT patients develop parathyroid cancer [34] . It is likely that several additional genes and genotype-phenotype correlations will be identified in the future.
A marked incidental increase in postmenopausal women and an association with high parity point towards an association with female hormones [41] . The coexistence of pHPT and breast cancer, confirmed in large population studies, has given rise to speculation concerning possible aetiologic links [42] [43] [44] . A wide expression of ERb1, ERb 2 and a significant transcriptional response associated with ER signalling has been observed in parathyroid tumours [45, 46] . It is known that a disturbance of oestrogen signalling is essential for the development and progression of certain neoplasia [47] . Primary hyperparathyroidism has also been associated with increased occurrence of certain other malignancies that persist unchanged after PTX suggesting a common predisposition or acquired disability to withstand environmental influence [43] .
Radiation, especially treatment in childhood, has been identified as a risk factor for the development of pHPT [48] . Contradicting results of an increased risk for developing pHPT after radioiodine treatment for hyperthyreosis have been reported [49, 50] .
Treatment with lithium, the gold standard therapy of bipolar disorders, results in hypercalcaemia in about a quarter of the cases [51] . Lithium-associated pHPT occurs either as single adenoma or as multiglandular disease, and its high prevalence justifies regular monitoring [51, 52] . Treatment with thiazide diuretics is also associated with hypercalcaemia that often persists after discontinuation of treatment and most likely merely unmasks underlying pHPT by reducing urinary calcium excretion [53, 54] .
To verify and evaluate the diagnosis
The diagnosis pHPT is biochemical and based on a high 'normal' iCa 2+ concentration in combination with elevated or inappropriately 'normal' PTH levels ( Table 1 ). The evaluation of the individual pHPT patient should always be based on a safe diagnosis and exclusion of differential diagnoses. Nonparathyroid causes of hypercalcaemia are generally associated with suppressed levels of PTH. FHH is an exception and is associated with a nonsuppressed secretion from seemingly normal parathyroid glands and is only distinguished by a low urinary calcium excretion and low calcium-to-creatinine clearance ratio (<0.01). Patients with FHH often have a family history of hypercalcaemia and/or unsuccessful parathyroid surgery [11, 28] .
The calcium level is often not constantly elevated in pHPT, and repeated sampling is necessary to verify the diagnosis. Approximately 50% of the circulating calcium is free, Ca 2+ . The rest is bound, mainly to albumin. Measurement of iCa 2+ more accurately reflects the true calcium and is to be preferred if available, yet is sensitive to changes in pH levels [55] . The measurement of total calcium should be corrected for serum albumin by 0.2 mmol L À1 for every 10 g L À1 in which the serum albumin is below 40 g L À1 [12] . The phosphate level is often low dependent of the phosphaturic effect that enhances phosphate excretion and calcium reabsorption to the kidneys. Despite the calciumconservative properties, hypercalciuria is common due to an increased filter load [12] .
It is recommended to measure inactive vitamin D (25OHD), in all pHPT patients [28] . PTH stimulates the conversion of 25OHD to the active form, 1,25OH 2 D. The inactive form is more stable, and the concentration in the serum of 25OHD is roughly 500-1000 times that of 1,25OH 2 D [56] . Vitamin D deficiency results in an increase in PTH, and replenishment of vitamin D is recommended when there is an insufficiency, which is defined by a 25OHD below 50 nmol L
À1
. Careful replenishment with cholecalciferol is associated with a limited risk of exacerbating hypercalcaemia and increasing urinary calcium excretion [57, 58] .
More than 10% of pHPT patients have a mutation in one of 11 identified genes [28, 33] . Genetic testing and counselling are important in patients at risk of carrying a mutation in order to confirm and undertake the appropriate screening for associated tumours, appropriate treatment, to identify family members at risk and to free those without risk from the burden of anxiety (Table 2 ) [11, 28] .
The risk of parathyroid cancer should be considered in patients with notable hypercalcaemia, and evidence of local invasion or a palpable parathyroid mass. It is often not possible to diagnose parathyroid cancer preoperatively. If parathyroid cancer is suspected, an en bloc resection including the ipsilateral thyroid lobe and the adjacent soft tissue is motivated [59] .
Normocalcaemic pHPT
Over the past decades, normocalcaemic pHPT has been recognized as a distinct variant of pHPT [60, 61] . The diagnosis is defined as a condition with a consistently elevated PTH in the presence of a normal levels of total and ionized serum calcium and the absence of any cause of secondary elevated PTH [28] . About 4-10% of pHPT patients have elevated PTH in combination with an isolated elevation of iCa 2+ and are not truly normocalcaemic [28, [62] [63] [64] . Because of the physiologic fluctuation in the plasma concentration, elevated PTH should be confirmed at least two occasions over a period of 3-to 6-month period [65] . Secondary or compensatory causes to elevated PTH are to be excluded (Table 3 ) [28] . Based on community cohorts, the prevalence of normocalcaemic pHPT has been estimated to 0.4-3% [66, 67] . The clinical characteristics and natural history of this variant are still not completely characterized. High rates of substantial skeletal and renal involvement with complications have been reported, most likely reflecting the fact that the diagnosis is often established as a result of biochemical evaluation after a clinical event, such as a fracture or a kidney stone disorder [31, 68] . The interpretation of the results must be valued based on risks of detection and selection biases, the majority of studies being retrospective and not including the measurement of iCa 2+ . Also, it is important to be reminded that, based on the definition of the normal range, two standard deviations about the mean, some individuals with PTH above the normal range will still be healthy [12] .
Recent reports indicate that the distribution of symptomatic and asymptomatic disorders is similar to the hypercalcaemic variant [12, 67, 68] . It is not clear if normocalcaemic PHPT represents a distinct clinical entity or is merely an early stage of the classical hypercalcaemic form [69] . General target-tissue resistance to PTH has been suggested as a possible aetiologic factor [69, 70] . Less extensive morphologic and functional derangement, milder excess in PTH, lower fasting urine calcium excretion, lower values of bone turnover markers, smaller adenoma and lastly a higher proportion of multiglandular involvement have all been reported from surgically verified cohorts of patients with normocalcaemic pHPT [70] [71] [72] [73] . The knowledge of the natural history of normocalcaemic pHPT is incomplete with contradicting reports of risk being published [31, 69, 74, 75] . Although evidence is lacking, an algorithm for monitoring of normocalcaemic pHPT has been included in the guidelines, recommending measurement of iCa 2+ and PTH and dual-energy X-ray absorptiometry (DXA) every 1-2 years (Fig. 2) [11] .
pHPT and effects on bone health
The skeletal benefits of parathyroid surgery in pHPT are well validated from both observational and randomized trials [11, [76] [77] [78] [79] [80] . Primary Fig. 2 Algorithm for monitoring and management of normocalcaemic primary hyperparathyroidism, copied from the guidelines [11] . *Dual-energy X-ray absorptiometry, **primary hyperparathyroidism, ***bone mineral density. hyperparathyroidism is associated with increased bone remodelling and an increased incidence of fractures [76, 77, 81, 82] . Osteitis fibrosa cystica is pathognomonic for pHPT, but is rare [15, 26, 83] . Osteoporosis, often first observed in the distal forearm, may progress silently until fragility fractures occur [81, 84] . Measurement of bone mineral density (BMD) at three sites (lumbar, hip and distal radius) using DXA should be included in the routine evaluation of patients with pHPT. DXA is not sensitive enough to detect early signs of bone resorption or to predict fracture risk. Decrease in bone turnover markers and improvement in BMD are observed also amongst patients without osteoporosis [77] . Data on fracture incidence in pHPT support the concepts of a reversible, increased risk [76, 78, 81] . The effect of conservative treatment as to the risk of vertebral fractures is not fully clarified [82] . In one study, PTX rather than treatment with bisphosphonates resulted in a reduced risk of fractures [78] . The change in micro skeletal features after successful parathyroid surgery and the coupling to fracture risk are still not clear. The benefits of newer approaches to evaluate the microstructure of the bone and to predict fracture risk in pHPT are yet to be evaluated [85, 86] . The current guidelines recommend parathyroid surgery if the T-score is less than À2.5 in any location, but also if the patient has a history of fragility fractures or if a vertebral fracture is present on an X-ray [11] .
In 2001, a bone-derived circulating glycoprotein, fibroblast growth factor-23 (FGF23), was cloned and characterized [87] . The primary targets of FGF23 are the kidneys and the parathyroids. The renal effects of FGF23 are suppression of the biosynthesis of vitamin D and inhibition of phosphate reabsorption. FGF23 also suppresses PTH gene expression and protein secretion through a direct bone-parathyroid feedback loop and may be an important modulator of PTH signalling [88] . FGF23 has also been identified as a risk factor for cardiovascular mortality in the community [89] .
Circulating FGF23 is increased in pHPT and is independently associated with the metabolic risk profile. The FGF23 levels fall after PTX but the long-term benefits of this remain to be established [90] .
pHPT and the kidneys
Damage to the kidneys is a strong indication for parathyroidectomy. Amongst pHPT patients with a history of kidney stones, hypercalciuria is the most common irregularity in the spectrum of metabolic abnormalities [91, 92] . Commonly, 24-h urinary calcium secretion correlates to bone remodelling and kidney function [93] . Nephrolithiasis and nephrocalcinosis can be asymptomatic, and therefore, indications for taking images of the kidneys should be generous. A calcium excretion above 10 mmol day À1 motivates more extensive evaluation [11, 93, 94] . The risk of developing new kidney stones decreases markedly after successful parathyroid surgery but pre-existing nephrocalcinosis and renal insufficiency remain [95] [96] [97] . If kidney stones recur after PTX, they are likely due to other metabolic disturbances such as high urinary pH, hypocitraturia and then citrate supplementation may be necessary [98] .
Nonclassical symptoms and risk factors associated with pHPT
The generally accepted indications for PTX are summarized in Table 2 . The definition of symptomatic pHPT is evolving to include even nonclassical symptoms and signs. In the last few decades, it has become evident that fewer patients than previously thought are truly asymptomatic and the nontraditional symptoms and signs should be considered when making the decision on the best treatment [99] [100] [101] [102] [103] [104] . Different tools to assess neuropsychological symptoms have been tested, and significant improvements have often been demonstrated after PTX [105] [106] [107] . The spectrum of neuropsychiatric and cognitive symptoms ranges from none at all to profound mental disability [108] . Some symptoms overlap with those of natural ageing and disease [109, 110] . Proximal muscle weakness, complaints of easy fatigability, generalized physical weakness and anxiety are common as are depression and mild cognitive dysfunction [111] . Improvements in QoL after PTX have also been reported in patients with asymptomatic pHPT [112, 113] . The problem is that many symptoms and signs possibly causally associated with pHPT are not diseasespecific, and it is not yet possible to predict the potential of reversibility in each individual case [11] .
Results from epidemiological and experimental studies suggest a causal link between increased plasma levels of PTH and cardiovascular disease [114] [115] [116] [117] [118] [119] [120] [121] . In addition to acting as the key regulator of the calcium homoeostasis, PTH exerts a positive, inotropic effect mediated by an increasing heart rate and coronary, arterial vasodilatation. The PTH seems to be involved in the development of cardiac hypertrophy, vascular remodelling and atherogenesis [119, 122] . Increased plasma levels in the community have been identified as a risk factor for metabolic abnormalities and for cardiovascular mortality [72, 115, 123, 124] . Interaction with aldosterone could contribute to this [125] . A disturbance in carbohydrate metabolism, such as an insulin hypersecretion, insulin resistance and dyslipidaemia, is more common in pHPT than in the general population [126, 127] . The effects of PTX on these metabolic disturbances have only been studied to a limited extent and with contradicting results [126] [127] [128] [129] [130] . Some data point to a reduction in both basal and stimulated insulin sensitivity, despite increased insulin secretion and potential recovery after PTX [129] [130] [131] .
Population-based studies from Europe have shown a clear association between pHPT and fatal and/or nonfatal cardiovascular disorders [18, 22, 72, [132] [133] [134] [135] . The cardiovascular morbidity associated with pHPT includes hypertension, cardiac hypertrophy, left ventricular dysfunction and myocardial ischaemia during exercise, arrhythmias as well as valvular calcifications with optional long-lasting improvements after PTX [134] [135] [136] [137] [138] [139] [140] [141] [142] . The mechanisms are not fully clarified but do involve endothelial dysfunction, increased vascular stiffness and increased cardiac afterload with ischaemia [136] [137] [138] [143] [144] [145] . Hypertension and left ventricular hypertrophy (LVH) are common in pHPT and appear to correlate to disease severity [118, 131, 134, 140, 141] . Control of the systolic blood pressure appears to be a crucial factor in the prevention of cardiovascular complications [146] . The Framingham Study confirmed that the risk of cardiovascular complications increased incrementally even with the systolic blood pressure within normal ranges [147] . It is also well established that measurement of 24-h ambulatory is superior to single office measurement in predicting cardiovascular risk [148] . The general opinion is that hypertension in pHPT is irreversible but the results from a handful of studies, including two with measurement of ambulatory blood pressure, have demonstrated the lowering of blood pressure after PTX [131, 142, 149, 150] . It can be hypothesized that PTX could be effective on reversing hypertension only if performed in the early phase of disease before structural changes with hypertrophy of resistance vessels evolve. This hypothesis is supported by a finding in a previous case-control study strictly restricted to subjects without known cardiovascular risk factors in which the pHPT patients had slightly higher SBP compared to the healthy control subjects. In this study, both SBP and regional systolic, myocardial velocities decreased after PTX [149] .
A key problem in the analyses of cardiovascular disturbances in pHPT is that many studies have been inadequately proportioned in order to guarantee adequate credibility for evaluating the effects of PTX. Furthermore, comparisons of results from different studies are biased by the mix of various pre-existing cardiovascular disorders and risk factors; thus, it has not been possible to predict the possibility of mitigating cardiovascular risk factors on a case-by-case basis. In a meta-analysis, it was recently demonstrated that PTX resulted in a decline in left ventricular mass [141] . The degree of improvement was related to the preoperative PTH levels.
Treatment of pHPT

Indications for parathyroid surgery according to the current guidelines
Parathyroidectomy is the only definite treatment of pHPT. At the Fourth International Workshop of Asymptomatic Primary Hyperparathyroidism [11] , the following indications were defined based upon available evidence to avoid potential deleterious effects of long-term hypercalcaemia:
• All patients with symptomatic pHPT are recommended surgery.
• Calcium concentration >0.25 mmol L À1 above the upper limit
• Osteoporosis defined as a T-score of less than À2.5 at any site (lumbar spine, hip, distal onethird radius) or a vertebral fracture.
• Renal insufficiency (creatinine clearance less than 60 mL min À1 ), kidney stones or nephrocalcinosis.
• Hypercalciuria (>10 mmol/24 h) and a biochemical stone risk profile.
• Under 50 years of age.
• Patient's choice, as long as there are no medical contraindications.
Normocalcaemic pHPT is included in the guidelines, and similar indications for surgery as well as for asymptomatic pHPT are recommended (Fig. 2) [11].
For pHPT patients not undergoing surgery, monitoring of calcium and bone mineral density measurement on an (bi-)annual basis is recommended [11] . Still, pHPT often remains undetected, and the indications for surgery are controversial [14, 151] . Referrals for surgery differ, dependent upon geographic region and if minimally invasive surgery can be offered [13] . On occasion, an untreated disease may progress silently with bone demineralization, and an increased calcium load on tissues until complications occurs. Yet, many pHPT patients, especially older patients, remain untreated. In a recent study, a linear decrease in the likelihood of PTX and longer delays from diagnosis to surgery for patients aged 60 and over was reported, though not explained by comorbidity or limited life expectancy. Only 24% of patients older than 70, who met the criteria for [76] surgery listed in the guidelines, underwent parathyroid surgery [152] . It is important to remember that PTX is a safe procedure even for elderly patients and with benefits similar to those experienced by younger patients [10, 152] .
Surgical treatment of pHPT
Performed by experienced endocrine surgeons, PTX is a safe and cost-effective procedure with a high cure rate. Failure to cure happens in 2.5-5%, and a surgeon's experience is predictive of the outcome [153] . Every patient with pHPT should be given the opportunity to receive information of potential benefits and risks from PTX [154] . The technique and efficacy has evolved at the same rate as improvements of different techniques for preoperative location and intraoperative PTH measurement [154] [155] [156] . Today, PTX is often performed as an outpatient procedure, and the post-operative recovery is short. Intraoperative PTH monitoring is useful in avoiding failure by detecting multiglandular disease, to guide the exploration according to differential jugular venous sampling and to verify an adenoma by ex vivo parathyroid aspiration.
The anatomy of the parathyroid glands varies greatly, and its complicated embryology and their slight size present a challenge. The weight of the adenoma can be less than 100 mg [157] . Ultrasound is a good screening method and makes it possible to evaluate concomitant thyroid nodules [134, 135] . Many endocrine surgeons perform the examination themselves [158, 159] . Multimodality imaging techniques combining nuclear medicine and computed tomography (CT) detectors contribute to improved sensitivity, especially for parathyroid adenomas with a location in the mediastinum, retropharyngeal and retroesophageal [157, 160] . It is important to keep in mind that parathyroid imaging is a localization procedure aimed to optimize the planning of surgery and is not a diagnostic method [154] .
The possibility of hereditary forms of pHPT has to be considered. Genetic testing and counselling are important to confirm and undertake appropriate screening for concomitant disorders. The surgical goal in these cases is to normalize the calcium homoeostasis sufficiently without complications from the disease or its surgical management [161, 162] . Bilateral exploration with subtotal parathyroidectomy is often preferred but not always necessary [162, 163] .
In case of persistent or recidivant hyperparathyroidism, the diagnosis should be re-evaluated, and a careful review of all previous investigations and the surgical procedure should be performed in order to evaluate the likelihood of a single or multiglandular disease and the likelihood of remaining normal parathyroid tissue [164] .
If a parathyroid carcinoma is suspected, the patient is best served if referred to specialist surgical centres that are experienced in oncological surgery. An en bloc resection, including the ipsilateral thyroid lobe and adjacent soft tissue, may be motivated [165] . A radical resection as first-line therapy reduces risk of recurrence and improves patient survival rates. Regular surveillance with control of iCa 2+ and PTH every 3-6 months is recommended. In the case of recurrent disease, surgery is motivated [166] .
Many patients with pHPT are underdiagnosed or undertreated, and referrals differ dependent upon cultural differences and the availability of minimally invasive surgery [13, 14, 151] . Only about 20-30% of all diagnosed patients in the United States are referred for parathyroid surgery [9, 13] . Elderly patients have the longest delay in diagnosis and the smallest chance of undergoing PTX despite the excellent results reported for geriatric patients [152] .
Medical treatment
Conservative follow-up is an alternative for patients with asymptomatic pHPT who do not meet the criteria or those patients who are unwilling to undergo PTX. The guidelines recommend active surveillance with annual control of iCa 2+ and PTH and periodic DXA for those patients with pHPT who are followed conservatively [11] .
All pHPT patients should be advised to stay adequately hydrated. The intake of calcium should adhere to the recommendations for the general population [167, 168] . The optimal level of 25OHD concentration is still a matter of controversy. Often, pHPT patients exhibit relatively low vitamin D levels that typically increase after successful PTX without specific intervention [131, 169] . Vitamin D deficiency is associated with a secondary rise in PTH. The guidelines prescribe cautious supplementation (e.g. 600-1000 IU cholecalciferol as a starting dose) for pHPT patients to achieve a 25OHD concentration >50 and up to 75 nmol L À1 [11, 167] . Higher levels of vitamin D might be beneficial in lowering PTH and improving bone mineral density but cautious monitoring of calcium levels in blood and urine is recommended to avoid exacerbating hypercalcaemia and increasing urinary calcium excretion [57, 167] .
Barring vitamin D substitution, pharmacological treatment is seldom indicated as an initial treatment with the exception of a few rare and acute situations. No medical treatment, single or combined, can achieve a curing of pHPT.
Bisphosphonates exert an antiresorptive effect by inhibition and apoptosis of osteoclasts. The results from small randomized trials have indicated a modest effect on bone mineral density in pHPT patients but no change in biochemistries and there are limited data on prevention of fracture [170, 171] . Treatment with bisphosphonates could be considered for patients with osteoporosis not undergoing PTX but is to be avoided for pHPT patients planned for PTX in order to avoid risk of post-operative hypocalcaemia and potential impairment of expected bone recovery [172, 173] .
Cinacalcet acts on the Ca 2+ -sensing receptors and is often effective in lowering iCa 2+-. The effect on the PTH concentration is less pronounced. Neither consistent effects on bone mineral density and urinary calcium excretion nor the risk of nephrolithiasis has been shown [167, 174, 175] . Side effects, especially nausea, are quite common. Cinacalcet is approved for treatment for pHPT patients with severe hypercalcaemia who are unable to undergo PTX but evidence regarding the safety of long-term treatment is limited.
Combination therapy with cinacalcet and bisphosphonates could be considered for pHPT patients who are unwilling to undergo surgery or have contraindications for surgery. Long-term data regarding benefits and safety are insufficient, and more studies are necessary [11] . Based on a revised cost-effectiveness analysis comparing PTX versus observation and considering fracture risk reduction, the surgical approach was the most costeffective [80] .
Treatment with oestrogen and selective oestrogen receptor modulators may reduce bone resorption in pHPT. Improvements in BMD have been observed in postmenopausal women but without any consistent effects on calcium or PTH levels, and the effect on fracture risk is not analysed. The potential risks and benefits have to be evaluated in individual cases [167, 176, 177] .
Treatment with thiazides results in the lowering of urinary calcium secretion. It is not shown, however, if this treatment reduces the risk of nephrolithiasis and the risk of exacerbating hypercalcaemia must be considered [178] .
Acute pHPT
In rare cases, pHPT presents itself as acute with markedly high and potentially life-threatening hypercalcaemia, occasionally in association with an infection or another intercurrent illness. A hypercalcaemic crisis is defined as a rapid onset of high serum calcium and signs of multiorgan dysfunction with gastrointestinal (nausea and vomiting, pancreatitis), renal (dehydration, oliguria), cardiovascular (ventricular arrhythmia, cardiac insufficiency) and/or neurological symptoms (muscle weakness, confusion, coma) [179] . The initial treatment is hydration with isotonic saline, 3-4 L daily and treatment of any underlying disorder. Medication contributing to hypercalcaemia, for example thiazides, should be discontinued. After correction of hypovolaemia, loop diuretics may be added to promote diuresis [179] . Measurement of PTH differentiates pHPT from malignancy [180] . The best timing for PTX is debatable but preparation for PTX should be initiated early on [181] . The most common cause is a benign parathyroid adenoma, and preoperative localization with neck ultrasound permits a focalized approach in the majority of cases [156, 182, 183] . Medical pretreatment with calcitonin, bisphosphonates or calcimimetics could be considered as a temporary measure [179, 181] . Postoperatively, the patient may need supplementation with calcium and vitamin D to replenish the calcium deficit [184] .
pHPT during pregnancy
In response to accelerating bone mineralization in the foetus, about 30 g of Ca 2+ is actively transported from the mother to the foetus during a normal pregnancy [185] . Gestational pHPT is probably underdiagnosed [186] . The incidence of pHPT in women of childbearing age has been estimated to 6-8 cases per 100 000 population per year, and through screening, disturbances in the calcium homoeostasis were observed in 5.1% of women aged between 40 and 50 years of age [21, 187] . During pregnancy, the foetus is maintained hypercalcaemic in relation to the mother, and the development of the foetal parathyroid glands is counteracted by maternal hypercalcaemia [188] . When the calcium efflux suddenly stops after delivery, the newborn is at risk of life-threatening hypocalcaemia with tetani and the mother risks a hypercalcaemic crisis. Symptoms during pregnancy such as fatigue, thirst and hyperemesis may be misinterpreted as related to pregnancy [186] . Conflicting data, as to increased risk of miscarriages and eclampsia is recorded, yet may possibly be biased as a result of selective reporting [186, [189] [190] [191] [192] . Parathyroidectomy after the first trimester is recommended for symptomatic patients. Preoperative localization with neck ultrasound usually allows for a focal approach. For asymptomatic patients with mild hypercalcaemia, a prompt follow-up without any medical treatment may be appropriate [186, 193, 194] . Bisphosphonates are contraindicated during pregnancy.
Challenges for future research concerning the indications for surgery in pHPT
More well-designed and adequately proportioned, prospective studies are necessary in order to identify the predictive factors of the effects of potential treatment on a case-by-case basis. These predictive factors, that is symptoms and measurement levels, may act as a guide when choosing the appropriate treatment whether it be surgery or active surveillance. Deciding upon the correct treatment is made easier by predicting the outcome of surveillance versus PTX on cardiovascular risk factors and of those nonclassical symptoms that affect quality of life.
Conclusion
In the last few decades, it has become evident that fewer patients than previously thought are truly asymptomatic. The only definite treatment for pHPT is PTX, and the procedure is safe and costeffective compared to conservative treatment. Recent data indicate that PTX is underutilized, especially in elderly pHPT patients. The decision of PTX should always be based on a safe diagnosis, and the potential benefits of curative treatment should not be outweighed by the risks of surgery or anaesthesia. The skeletal and renal benefits of PTX are well validated. For the nonclassical symptoms and signs often associated with pHPT, it is often not possible to predict the effects of PTH on an individual basis. Preoperative localization facilitates the surgical procedure. Patients at risk of hereditary pHPT should be verified prior to surgery. FHH should be excluded in order to avoid an unnecessary PTX.
